1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Certara, Inc.

Certara, Inc.

CERT
Certara, Inc.US flagNASDAQ Global Select
8.04
USD
-0.11
- -
1.25BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.24
1.36
1.83
1.91
2.14
2.23
2.4
2.61
2.59
Basic EPS, GAAP
-0.25
-0.06
-0.37
-0.09
0.09
-0.35
-0.08
-0.01
-0.43
Free Cash Flow per Basic Share
- -
0.19
0.28
0.4
0.59
0.52
0.5
0.6
0.52
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.23
3.22
5.37
6.53
6.77
6.55
6.58
6.68
6.34
Tangible Book Value per Share
-3.15
-2.95
-0.61
-1.09
-0.78
-0.98
-1.14
-0.99
-0.63
Basic Weighted Avg Shares
132
153
133
150
157
159
160
160
158
Sales/Revenue/Turnover
164
209
244
286
336
354
385
419
408
Operating Margin (%)
-2.84
9.41
-10.03
4.75
9.69
1.75
-0.45
5.02
-0.16
Depreciation Expense
37
42
43
45
52
56
68
75
76
Net Income, GAAP
-33
-9
-49
-13
15
-55
-12
-2
-68
Effective Tax Rate (%)
- -
- -
- -
- -
21.46
- -
- -
120.94
- -
Profit Margin (%)
-20.31
-4.28
-20.28
-4.64
4.39
-15.62
-3.13
-0.38
-16.75
Working Capital
3
25
271
183
239
210
165
162
190
LT Debt
405
397
294
300
300
295
304
299
296
Total Equity
493
492
822
1,042
1,080
1,047
1,059
1,063
967
Return on Invested Capital (%)
- -
- -
- -
- -
1.86
- -
- -
-0.32
- -
Return on Capital (%)
- -
- -
- -
- -
2.1
- -
- -
-0.42
- -
Return on Common Equity (%)
- -
-1.81
-7.52
-1.42
1.39
-5.21
-1.14
-0.15
-6.72

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7
3
3
LT Borrowings
290
290
289
LT Finance Leases
8
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
159
153
152
Market Capitalization
1,402
874
999

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
315
271
312
Cash, Cash Equivalents & STI
189
149
184
Accounts Receivable, Net
95
83
81
Inventories
- -
- -
- -
Total Current Liabilities
153
144
122
Payables & Accruals
11
13
16
ST Debt
7
3
3
Deferred Revenue
75
76
77

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
5.77%
0.39%
Free Cash Flow
- -
23.93%
19.71%
Net Income, GAAP
- -
-184.99%
-86.76%
Sales/Revenue/Turnover
- -
11.56%
8.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
97
93
95
100
385
2025
106
92
105
104
419
2026
107
93
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.08
-0.01
0.04
-0.08
2025
0.03
-0.01
0.01
-0.04
-0.01
2026
-0.06
-0.36
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Jon Resnick
Full Time Employees
1,546
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
4 Radnor Corporate Center Radnor PA United States of America 19087
IPO Date
Dec 11, 2020
CIK
0001827090
Website
certara.com
Similar Companies
Veeva Systems Inc. (0LO3.L)
Healthcare Integrated Technologies, Inc. (HITC)
Imaging Biometrics Ltd. (IBAI.L)
Evolent Health, Inc. (EVH)
Cambridge Cognition Holdings Plc (COG.L)
RaySearch Laboratories AB (publ) (RAY-B.ST)
Business
Certara, Inc. (Nasdaq: CERT) provides biosimulation software, technology-enabled services, and solutions for model-informed drug development (MIDD) in the biopharmaceutical industry; its core offerings include mechanistic and empirical biosimulation platforms such as Simcyp PBPK Simulator; empirical PK/PD biosimulation platform; scientific informatics platforms like D360 and Chemaxon products including Design Hub and JChem Engines; clinical outcomes databases; regulatory submissions authoring and management software; market access communication platforms; data standardization and compliance software; and services encompassing drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, health economics and outcomes research (HEOR), and real-world evidence solutions. Founded in 2008 through the combination of Tripos International and Pharsight Corporation and headquartered at 4 Radnor Corporate Center, Suite 350, Radnor, Pennsylvania, the company operates globally with offices in the U.S., Canada, U.K., France, Germany, Switzerland, India, Japan, China, Australia, the Netherlands, and the Philippines, serving over 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across more than 70 countries. In recent developments, Certara completed the acquisition of Chemaxon in October 2024 to enhance its scientific informatics and predictive biosimulation capabilities from discovery through commercialization, integrating precision chemistry tools into its D360 applications and Simcyp simulator while leveraging Certara.AI for improved drug discovery insights; the company relocated its corporate headquarters to Radnor, Pennsylvania in 2024 to support workforce growth and strengthen its presence in the life sciences hub near Philadelphia; and it reported preliminary first-quarter 2025 financial results in April 2025 with revenue of $106.0 million, up from $96.7 million in the prior year, alongside 12% bookings growth and a $100 million share repurchase authorization.

Company News

APIChatGPT

  • seekingalpha.com

    Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

  • marketbeat.com

    Certara Q2 Earnings Call Highlights

  • zacks.com

    Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

  • globenewswire.com

    Certara Reports Second Quarter 2026 Financial Results

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • prnewswire.com

    An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • globenewswire.com

    Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • benzinga.com

    Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

  • globenewswire.com

    Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • globenewswire.com

    Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm

  • globenewswire.com

    Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm

  • globenewswire.com

    Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

  • globenewswire.com

    Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses